Highest-materiality recent filing
Nordson Q2 record sales $741M (+8% YoY) and adj EPS $2.86 (+18% YoY); raises FY outlook
Net income $117M, $2.09 diluted EPS; adjusted diluted EPS $2.86 (record, +18% YoY).
Nordson shareholders elect three directors, ratify auditor, approve advisory say-on-pay
Christopher Mapes, Michael Merriman Jr., Sundaram Nagarajan elected to board until 2029; all received >42M votes for.
Nordson Q1 record sales $669M (+9% YoY); raises FY adj. EPS guidance to $11.00-$11.60
Q1 GAAP EPS $2.38 (up 44% YoY); adjusted EPS $2.37 (record, up 15%).
Nordson enters $1.2B revolving credit facility, repays $248M term loans
New $1.2B senior unsecured multicurrency revolving credit facility matures January 30, 2031.
Nordson reports record FY2025 sales of $2.8B; adj. EPS $10.24, up 5% YoY
Q4 sales $752M (+1% YoY); diluted EPS $2.69; adj. diluted EPS $3.03 (+9% YoY).
Nordson adopts Executive Severance Policy effective November 1, 2025
Policy provides severance benefits for US-based executive officers on qualifying termination outside change-in-control period.
Nordson Q3 sales $742M (+12%), adjusted EPS $2.73 (+13%); board adds $500M buyback
Q3 sales $742M, up 12% YoY; organic sales up 2%; acquisition impact 8%.
Nordson appoints Joseph M. Rutledge as VP and Chief Accounting Officer
Joseph M. Rutledge appointed VP and Chief Accounting Officer effective July 14, 2025.
Nordson separation agreement for departing segment leader Lovass: $832,759 cash, continued vesting
Stephen Lovass ceased as Medical and Fluid Solutions segment leader; assists transition until June 1, 2025, then separates.
Nordson Q2 FY2025 sales $683M (+5%), adj EPS $2.42 beats midpoint; Q3 guide $710-750M
Q2 sales $683M (+5% YoY) with 8% acquisition benefit offset by 2% organic decline.
the Original Form 8-K reported that, on April 28, 2025, Stephen Lovass ceased to serve as segment leader for the Medical and Fluid Solutions Segment of Nordson Corporation
Max materiality 0.85 · Median 0.68 · Most common event earnings